62 related articles for article (PubMed ID: 11951375)
1. Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.
Pigors M; Patzelt S; Reichhelm N; Dworschak J; Khil'chenko S; Emtenani S; Bieber K; Hofrichter M; Kamaguchi M; Goletz S; Köhl G; Köhl J; Komorowski L; Probst C; Vanderheyden K; Balbino B; Ludwig RJ; Verheesen P; Schmidt E
J Pathol; 2024 Feb; 262(2):161-174. PubMed ID: 37929639
[TBL] [Abstract][Full Text] [Related]
2. Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein.
Cho YT; Lee CH; Lee JY; Chu CY
J Dermatol Sci; 2024 Apr; 114(1):44-51. PubMed ID: 38508975
[TBL] [Abstract][Full Text] [Related]
3. Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients.
Gaudin O; Seta V; Alexandre M; Bohelay G; Aucouturier F; Mignot-Grootenboer S; Ingen-Housz-Oro S; Bernardeschi C; Schneider P; Mellottee B; Caux F; Prost-Squarcioni C
Front Immunol; 2018; 9():1030. PubMed ID: 29881377
[TBL] [Abstract][Full Text] [Related]
4. Study of original B cells producing pathogenic IgG and IgA autoantibodies in anti-BP180-type mucous membrane pemphigoid.
Hayashi D; Hashimoto T; Mine M; Ishii N; Hashimoto K; Tsuchisaka A; Tsuruta D
Arch Dermatol Res; 2024 May; 316(5):169. PubMed ID: 38734797
[No Abstract] [Full Text] [Related]
5. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid.
Liu Z; Shipley JM; Vu TH; Zhou X; Diaz LA; Werb Z; Senior RM
J Exp Med; 1998 Aug; 188(3):475-82. PubMed ID: 9687525
[TBL] [Abstract][Full Text] [Related]
6. Accurate diagnosis of bullous pemphigoid requires multiple health care visits.
Leisti P; Pankakoski A; Jokelainen J; Varpuluoma O; Huilaja L; Panelius J; Tasanen K
Front Immunol; 2023; 14():1281302. PubMed ID: 38090583
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Infantile Bullous Pemphigoid: Triggering by COVID-19 Is Speculative.
Rosińska-Więckowicz A; Jałowska M; Bowszyc-Dmochowska M; Dmochowski M
Front Med (Lausanne); 2021; 8():760823. PubMed ID: 34881262
[TBL] [Abstract][Full Text] [Related]
8. Potential correlation between anti-laminin 332 autoantibodies and malignant tumours in anti-BP180-type mucous membrane pemphigoid.
Li X; Pas HH; Qian H; Rashid H; Horvath B; Yilmaz K; van Beek N; Schmidt E; Zillikens D; Ishii N; Tsuruta D; Hashimoto T
Clin Exp Dermatol; 2024 Apr; ():. PubMed ID: 38634807
[No Abstract] [Full Text] [Related]
9. Diagnostics of autoimmune blistering disorders: an experience of a single tertiary referral centre.
Adaszewska A; Woźniak K; Kalińska-Bienias A; Smolarczyk K; Kowalewski C
Postepy Dermatol Alergol; 2022 Jun; 39(3):446-453. PubMed ID: 35950139
[TBL] [Abstract][Full Text] [Related]
10. Linear Immunoglobulin a Bullous Dermatosis in Children.
Mori F; Saretta F; Liotti L; Giovannini M; Castagnoli R; Arasi S; Barni S; Mastrorilli C; Pecoraro L; Caminiti L; Marseglia GL; Barbaud A; Novembre E
Front Pediatr; 2022; 10():937528. PubMed ID: 35874598
[TBL] [Abstract][Full Text] [Related]
11. Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology.
Vale ECSD; Dimatos OC; Porro AM; Santi CG
An Bras Dermatol; 2019 Apr; 94(2 Suppl 1):48-55. PubMed ID: 31166403
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy.
Leuci S; Amato M; Calabria E; Piscopo R; Tranfa F; Spagnuolo G; Mignogna MD
J Ophthalmol; 2018; 2018():8372146. PubMed ID: 30327726
[TBL] [Abstract][Full Text] [Related]
13. Bullous Pemphigoid with Lymphocytic Colitis: A Case Report and Short Literature Review.
Sperl A; Bauer JW; Meyersburg D
Dermatol Ther (Heidelb); 2016 Sep; 6(3):437-41. PubMed ID: 27469343
[TBL] [Abstract][Full Text] [Related]
14. Organ-specific and memory treg cells: specificity, development, function, and maintenance.
Gratz IK; Campbell DJ
Front Immunol; 2014; 5():333. PubMed ID: 25076948
[TBL] [Abstract][Full Text] [Related]
15. Biochip technology for the serological diagnosis of bullous pemphigoid.
Zarian H; Saponeri A; Michelotto A; Zattra E; Belloni-Fortina A; Alaibac M
ISRN Dermatol; 2012; 2012():237802. PubMed ID: 23346412
[TBL] [Abstract][Full Text] [Related]
16. Development of ocular disease in patients with mucous membrane pemphigoid involving the oral mucosa.
Higgins GT; Allan RB; Hall R; Field EA; Kaye SB
Br J Ophthalmol; 2006 Aug; 90(8):964-7. PubMed ID: 16613917
[TBL] [Abstract][Full Text] [Related]
17. The role of topical corticosteroids in bullous pemphigoid in the elderly.
Joly P; Fontaine J; Roujeau JC
Drugs Aging; 2005; 22(7):571-6. PubMed ID: 16038572
[TBL] [Abstract][Full Text] [Related]
18. BP180 as the common autoantigen in blistering diseases with different clinical phenotypes.
Zillikens D
Keio J Med; 2002 Mar; 51(1):21-8. PubMed ID: 11951375
[TBL] [Abstract][Full Text] [Related]
19. Bullous pemphigoid and cicatricial pemphigoid autoantibodies react with ultrastructurally separable epitopes on the BP180 ectodomain: evidence that BP180 spans the lamina lucida.
Bédane C; McMillan JR; Balding SD; Bernard P; Prost C; Bonnetblanc JM; Diaz LA; Eady RA; Giudice GJ
J Invest Dermatol; 1997 Jun; 108(6):901-7. PubMed ID: 9182819
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
